Join Medicilon at the 21st San Diego Biopharma Conference (SABPA 2023)

2023-08-24

Page View：

Join Medicilon at the 21^st San Diego Biopharma Conference in the beautiful San Diego. This time, you can not only visit our table, but also focus the speech “Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon” by our CEO, Dr. Chunlin Chen.

Date: September 30, 2023, 9:00 am - 5:00 pm

Location: Hilton San Diego/Del Mar

About 21^st San Diego Biopharma Conference

The SABPA San Diego BioPharma Conference promises to be a groundbreaking event in the field of biotechnology and pharmaceuticals. The conference will bring together both academia and industry leaders, researchers, and visionaries from around the world to share their insights, latest discoveries and innovations.

This gathering brings together exceptional experts and leaders in both academia and industry to explore the latest breakthroughs, innovations, and opportunities in the field. The conference program boasts a notable lineup of top-level executives, distinguished scientists, and successful entrepreneurs. Topics include in vivo cell engineering and gene editing, protein homeostasis in neurodegeneration, histidine phosphorylation in cancer therapy, the establishment of biotech start-ups within venture-funded incubators and more. This event presents a unique opportunity to acquire knowledge, expand professional networks, and actively contribute to the ongoing transformation within the bio-pharmaceutical industry.

About Medicilon

Medicilon is an integrated contract research organization (CRO) providing comprehensive one-stop services from initial idea to IND enabling studies and API manufacture for biotech, pharmaceutical companies and research institutions. With 20 years’ experience in serving drug discovery, we have built an integrated technical platform covering, small molecule and large molecule drug discovery, in vivo and in vitro pharmacology, and preclinical IND enabling capabilities, to support drug development for today’s dynamic industry.

Our clients include not only pharmaceutical companies such as Roche, GSK and AZ, but also many global SMEs including start-up companies, R&D companies and Universities. Medicilon delivers both non-GLP and GLP safety studies generating data that is fully accepted by FDA, EMA, NMPA and TGA agencies. Our GLP in vivo laboratory is an AAALAC accredited international standard laboratory, audited and approved by NMPA and FDA. Since 2015, Medicilon has successfully assisted 385+ new drug and generic drug projects to enter clinical trials by NMPA, FDA, and TGA, which accelerates the customer's new drug development process!

Medicilon develops new technology platforms constantly, working in partnership with our global clients to deliver demanding and innovative novel drug research. Up to 2022, Medicilon has successfully developed more than 100 preclinical candidates for our global clients. In the preclinical candidate stage, Medicilon screens out lead compounds with high activity and selectivity through high-throughput screening and AI design, and further optimize the lead compounds (including physicochemical properties, early druggability, metabolic stability, pharmacokinetics, toxicity prediction, etc.) to obtain the candidate compound (PCC) and back-up compound, to further enable the research work in the IND stage.

At Medicilon, we are passionate about our role in novel drug discovery and research to improve people's health. We focus on timelines and applying multidisciplinary perspective in resolving our global clients’ research challenges and providing cost effective solutions to deliver quality data in every stage of drug research and development.

20 Years of Excellence

2000+ Active Clients Worldwide

3100+ Scientists and Service Personnel

84600+ Square Feet of Lab Space

385+ IND Approved by FDA, NMPA, EMA, and TGA

Services and Solutions

Drug Discovery

❖Chemistry Research

❖Biology Research

❖Early DMPK Research

CMC Services

❖Intermediates